Table 3 Treatment modalities, stratified by NCCN risk group, of men with PCa in the study region, metropolitan Melbourne and the rest of Victoria
NNCCN Risk group | Low* | Intermediate* | High* | Very high/Metastatic* | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study region, n (%) | Metropolitan, n (%) | Rest of Victoria, n (%) | Study region, n (%) | Metropolitan, n (%) | Rest of Victoria, n (%) | Study region, n (%) | Metropolitan, n (%) | Rest of Victoria, n (%) | Study region, n (%) | Metropolitan, n (%) | Rest of Victoria, n (%) | |
No treatment/AS/WW | 46 (63.0 %) | 244 (51.0 %) | 337 (37.0 %) | 36 (31.9 %) | 161 (15.1 %) | 201 (10.7 %) | 8 (8.2 %) | 45 (7.3 %) | 44 (5.1 %) | 1 (2.3 %) | 4 (3.0 %) | 3 (1.2 %) |
Surgery (Prostatectomy) | 14 (19.2 %) | 142 (29.7 %) | 400 (43.9 %) | 31 (27.4 %) | 543 (51.0 %) | 1,104 (58.5 %) | 13 (13.4 %) | 168 (27.3 %) | 313 (36.1 %) | 2 (4.5 %) | 9 (6.8 %) | 21 (8.6 %) |
EBRT/EBRT + HDR | 5 (6.8 %) | 33 (6.9 %) | 56 (6.1 %) | 23 (10.4 %) | 161 (15.1 %) | 345 (18.3 %) | 35 (36.1 %) | 233 (37.8 %) | 311 (35.9 %) | 11 (25.0 %) | 60 (45.1 %) | 109 (44.5 %) |
EBRT + Surgery | 1 (1.4 %) | 5 (1.0 %) | 26 (2.9 %) | 3 (2.7 %) | 78 (7.3 %) | 108 (5.7 %) | 5 (5.2 %) | 60 (9.7 %) | 96 (11.1 %) | 0 (0.0 %) | 6 (4.5 %) | 9 (3.7 %) |
LDR | 5 (6.8 %) | 22 (4.6 %) | 69 (7.6 %) | 7 (6.2 %) | 53 (5.0 %) | 68 (3.6 %) | 0 (0.0 %) | 0 (0.0 %) | 1 (0.1 %) | 1 (2.3 %) | 0 (0.0 %) | 0 (0.0 %) |
HDR | 0 (0.0 %) | 0 (0.0 %) | 1 (0.1 %) | 1 (0.9 %) | 6 (0.6 %) | 3 (0.2 %) | 0 (0.0 %) | 1 (0.2 %) | 1 (0.1 %) | 1 (2.3 %) | 0 (0.0 %) | 1 (0.4 %) |
BT-Unknown | 1 (1.4 %) | 8 (1.7 %) | 5 (0.5 %) | 0 (0.0 %) | 8 (0.8 %) | 6 (0.3 %) | 0 (0.0 %) | 1 (0.2 %) | 2 (0.2 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) |
ADT | 0 (0.0 %) | 3 (0.6 %) | 2 (0.2 %) | 9 (8.0 %) | 13 (1.2 %) | 23 (1.2 %) | 34 (35.1 %) | 92 (14.9 %) | 79 (9.1 %) | 23 (52.3 %) | 41 (30.8 %) | 84 (34.3 %) |
Chemotherapy | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 0 (0.0 %) | 1 (1.0 %) | 1 (0.2 %) | 1 (0.1 %) | 4 (9.1 %) | 5 (3.8 %) | 13 (5.3 %) |
Other | 0 (0.0 %) | 5 (1.0 %) | 4 (0.4 %) | 0 (0.0 %) | 6 (0.6 %) | 2 (0.1 %) | 0 (0.0 %) | 0 (0.0 %) | 1 (0.1 %) | 0 (0.0 %) | 1 (0.8 %) | 0 (0.0 %) |
Not known | 1 (1.4 %) | 16 (3.3 %) | 11 (1.2 %) | 3 (2.7 %) | 35 (3.3 %) | 27 (1.4 %) | 1 (1.0 %) | 15 (2.4 %) | 18 (2.1 %) | 1 (2.3 %) | 7 (5.3 %) | 5 (2.0 %) |
Total | 73 (100 %) | 478 (100 %) | 911 (100 %) | 113 (100 %) | 1,064 (100 %) | 1,887 (100 %) | 97 (100 %) | 616 (100 %) | 867 (100 %) | 44 (100 %) | 133 (100 %) | 245 (100 %) |
Median (IQR) days to initial treatment | N/A | N/A | N/A | 101 (56–191) | 71.5 (44–119) | 61 (39–103) | 57 (34–90) | 49.5 (31–84.25) | 43 (27–65) | 27 (6–67.5) | 27 (9–58.5) | 19.5 (7–50) |
Median (IQR) km to treating hospital | 31.6 (18.9-69.3) | 11.8 (6.2-25.9) | 21.6 (9.1-55.5) | 56.4 (23.1-114.9) | 13.1 (7.2-27.4) | 20.7 (10–51.4) | 42.3 (19–82.7) | 11.7 (6.2-25.7) | 20.8 (9.8-61.3) | 39.4 (19.2-80.7) | 11.4 (5.5-24.7) | 25.6 (11.2-71.6) |